This is a biopharmaceutical company primarily_engaged in the research,_development and commercialization of prescription ophthalmic pharmaceuticals. Its efforts are focused_on CAUSE_OF_DEATH affecting the lining in the back of the eye, or retina, because these CAUSE_OF_DEATH are either not treated pharmacologically or are in need of improved treatments. The COUNTRY - based company has a registered office_located in CITY,_STATE_OR_PROVINCE. The company was_created in DATE DATE with the vision to_bring innovative products to_treat eye CAUSE_OF_DEATH, specifically CAUSE_OF_DEATH that affect the retina, and to_be guided_by its experience of knowing the right things to do, and its desire to do the right thing in its SET approach to the business. Its_main focus is on Iluvien, which it is developing for the treatment of diabetic macular edema, or DME. DME is a CAUSE_OF_DEATH of the retina which affects individuals with CAUSE_OF_DEATH and can lead to severe vision loss and blindness. Iluvien is a tiny cylindrical polyimide tube that contains NUMBER microgram of fluocinolone acetonide (FA), a known corticosteroid with a history of treating ocular CAUSE_OF_DEATH. Iluvien is administered as an intravitreal insert and its design provides for a sustained - release that delivers a low, steady SET dose of FA over an anticipated DURATION_DURATION_DURATION_DURATION period. LOCATION is inserted into the patient 's eye in the retinal TITLE 's office using a procedure very similar to intravitreal injection, a procedure commonly employed by retina specialists. Its_mission is to pursue treatments for CAUSE_OF_DEATH affecting the back of the eye, or retina, because these CAUSE_OF_DEATH are_not well treated with DATE therapies and will affect millions of people in its aging populations.